Literature DB >> 25139763

High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.

Samantha A Meenach1, Kimberly W Anderson, J Zach Hilt, Ronald C McGarry, Heidi M Mansour.   

Abstract

Inhalable lung surfactant-based carriers composed of synthetic phospholipids, dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG), along with paclitaxel (PTX), were designed and optimized as respirable dry powders using organic solution co-spray-drying particle engineering design. These materials can be used to deliver and treat a wide variety of pulmonary diseases with this current work focusing on lung cancer. In particular, this is the first time dry powder lung surfactant-based particles have been developed and characterized for this purpose. Comprehensive physicochemical characterization was carried out to analyze the particle morphology, surface structure, solid-state transitions, amorphous character, residual water content, and phospholipid bilayer structure. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) spectroscopy. PTX loading was high, as quantified using UV-VIS spectroscopy, and sustained PTX release was measured over weeks. In vitro cellular characterization on lung cancer cells demonstrated the enhanced chemotherapeutic cytotoxic activity of paclitaxel from co-spray-dried DPPC/DPPG (co-SD DPPC/DPPG) lung surfactant-based carrier particles and the cytotoxicity of the particles via pulmonary cell viability analysis, fluorescent microscopy imaging, and transepithelial electrical resistance (TEER) testing at air-interface conditions. In vitro aerosol performance using a Next Generation Impactor™ (NGI™) showed measurable powder deposition on all stages of the NGI and was relatively high on the lower stages (nanometer aerodynamic size). Aerosol dispersion analysis of these high-performing DPIs showed mass median diameters (MMADs) that ranged from 1.9 to 2.3 μm with excellent aerosol dispersion performance as exemplified by high values of emitted dose, fine particle fractions, and respirable fractions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139763      PMCID: PMC4245438          DOI: 10.1208/s12249-014-0182-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  41 in total

Review 1.  Drug properties affecting aerosol behavior.

Authors:  S Suarez; A J Hickey
Journal:  Respir Care       Date:  2000-06       Impact factor: 2.258

2.  Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.

Authors:  Missak Haigentz; Roman Perez-Soler
Journal:  Methods Mol Med       Date:  2003

3.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

Authors:  P O'Hara; A J Hickey
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 4.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 5.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 6.  Recent advances in pulmonary drug delivery using large, porous inhaled particles.

Authors:  D A Edwards; A Ben-Jebria; R Langer
Journal:  J Appl Physiol (1985)       Date:  1998-08

7.  Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier.

Authors:  Christopher I Grainger; Leona L Greenwell; David J Lockley; Gary P Martin; Ben Forbes
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 8.  Pulmonary surfactant therapy.

Authors:  A H Jobe
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

Review 9.  Development of inhalational agents for oncologic use.

Authors:  S Sharma; D White; A R Imondi; M E Placke; D M Vail; M G Kris
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

10.  Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.

Authors:  Chun-Woong Park; Xiaojian Li; Frederick G Vogt; Don Hayes; Joseph B Zwischenberger; Eun-Seok Park; Heidi M Mansour
Journal:  Int J Pharm       Date:  2013-06-29       Impact factor: 5.875

View more
  19 in total

Review 1.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

2.  Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.

Authors:  Priya Muralidharan; Don Hayes; Stephen M Black; Heidi M Mansour
Journal:  Mol Syst Des Eng       Date:  2016-01-27

3.  Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

4.  Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.

Authors:  Alexan I Gomez; Maria F Acosta; Priya Muralidharan; Jason X-J Yuan; Stephen M Black; Don Hayes; Heidi M Mansour
Journal:  Pulm Pharmacol Ther       Date:  2020-10-31       Impact factor: 3.410

Review 5.  Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment.

Authors:  Moez Ghumman; Dinesh Dhamecha; Andrea Gonsalves; Lauren Fortier; Parand Sorkhdini; Yang Zhou; Jyothi U Menon
Journal:  Eur J Pharm Biopharm       Date:  2021-04-18       Impact factor: 5.589

Review 6.  Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems.

Authors:  Piyush Mehta
Journal:  J Drug Deliv       Date:  2016-10-27

Review 7.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12

Review 8.  Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.

Authors:  Mehak Passi; Sadia Shahid; Sankarakuttalam Chockalingam; Isaac Kirubakaran Sundar; Gopinath Packirisamy
Journal:  Int J Nanomedicine       Date:  2020-05-28

9.  POxylated Dendrimer-Based Nano-in-Micro Dry Powder Formulations for Inhalation Chemotherapy.

Authors:  Rita B Restani; Rita F Pires; Anna Tolmatcheva; Rita Cabral; Pedro V Baptista; Alexandra R Fernandes; Teresa Casimiro; Vasco D B Bonifácio; Ana Aguiar-Ricardo
Journal:  ChemistryOpen       Date:  2018-07-25       Impact factor: 2.911

10.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:  Maria F Acosta; Michael D Abrahamson; David Encinas-Basurto; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.